OUTCOMES OF TRIPLE NEGATIVE BREAST CANCER IN EARLY BREAST CANCER WITH NEO ADJUVANT CHEMOTHERAPY
Submission: 07 December 2025 | Acceptance: 02 March 2026 | Publication: 29 April 2026
1Dr Bushra Malik, 2Dr Muhammad Tariq, 3Dr Asiya Hassan, 4Dr Maryam bibi, 5Dr Kiran Shaheen, 6Dr Irum Sabir
1Pgr medical oncology MTI KTH PESHAWAR
2Assistant professor Department of medical oncology MTI KTH PESHAWAR
3Consultant IKD PESHAWAR
4Pgr medical oncology MTI KTH PESHAWAR
5Pgr medical oncology MTI KTH PESHAWAR
6Associate Professor Department of surgery / breast unit, MTI KTH PESHAWAR
Corresponding: Dr Muhammad Tariq, Assistant professor Department of medical oncology MTI KTH PESHAWAR
Abstract:
Objectives: To determine the outcomes of triple negative breast cancer in early breast cancer with neo adjuvant chemotherapy.
Materials and Methods: After approval from the review board, patients were enrolled following written informed consent for voluntary participation. Data were collected from all participants, including detailed physical examination findings and medical history. Demographic variables were noted. Patients received protocol-based treatment with either an immunotherapy-based regimen or standard neoadjuvant anthracycline-based chemotherapy every three weeks for three cycles, along with standard supportive medications. Following treatment completion, surgery was performed and specimens were sent for histopathological evaluation. Data were recorded in a questionnaire and analyzed with SPSS 26.
Results: The majority of patients were between 31 and 40 years old, with a mean age of 42.69 ± 9.71 years and a mean BMI of 22.48 ± 4.12 kg/m². Illiteracy, housewife position, urban living, right-sided sickness, and middling socioeconomic level were more prevalent. While there was no discernible correlation between treatment response and age, breast laterality, or BMI, nearly half obtained complete remission.
Conclusion: It was concluded that neoadjuvant chemotherapy plays a crucial role in the treatment of early triple-negative breast cancer, and that the best indicator of enhanced survival is pathological full response. To improve therapy response and optimize treatment techniques, more research is advised.
Key words: Triple negative breast cancer, neo adjuvant chemotherapy, complete response.